Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators

Europace

Volumn 12, Issue 5, 2010, Pages 618-625

  Van Herendael, Hugo ^a   Pinter, Arnold ^a   Ahmad, Kamran ^a   Korley, Victoria ^a   Mangat, Iqwal ^a   Dorian, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Antiarrhythmic drugs; Implantable cardioverter defibrillator

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; CELIVARONE; DOFETILIDE; DRONEDARONE; FLECAINIDE; LIDOCAINE; MEXILETINE; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; CATHETER ABLATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; MAINTENANCE DRUG DOSE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SINUS NODE CONDUCTION VELOCITY; UNSPECIFIED SIDE EFFECT; ARRHYTHMIAS, CARDIAC; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; HUMANS; PATIENT SELECTION; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 77951960223     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq073     Document Type: Review

References (62)

1. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck K-H, Zipes DP et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trial. Eur Heart J 2000;21:2071-8.
2. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: elevenyear follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004;110:112-6.
3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
4. Lee KL, Hafley G, Fisher JD, Gold MR, Prystowsky EN, Talajic M et al. Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation 2002;106:233-8.
5. Gradaus R, Block M, Brachmann J, Breithardt G, Huber HG, Jung W et al. Mortality, morbidity and complications in 3344 patients with implantable cardioverterdefibrillators: result from the Germany ICD registry EURID. Pacing Clin Electrophysiol 2003;26:1511-8.
6. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. For the multicenter automatic defibrillator implantation trial II investigators. N Engl J Med 2002;346:877-83.
7. Steinberg JS, Martins J, Sadanandan S, Goldner B, Menchavez E, Domanski M et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001;142:520-9.
8. Sola CL, Bostwick JM. Implantable cardioverter-defibrillators, induced anxiety, and quality of life. Mayo Clin Proc 2005;80:232-7.
9. Irvine J, Dorian P, Baker B, O'Brien BJ, Roberts R, Gent M et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002;144:282-9.
10. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial. Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-94.
11. Piotrowicz K, Noyes K, Lyness JM, McNitt S, Andrews ML, Dick A et al. Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II. Eur Heart J 2007;28:601-7.
12. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17.
13. Dorian P, Al-Khalidi HR, Hohnloser SH, Brum JM, Dunnmon PM, Pratt CM et al. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol 2008;52:1076-83.
14. Gronefeld GC, Mauss O, Li YG, Klingenheben T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J Cardiovasc Electrophysiol 2000;11:1208-14.
15. Stein KM, Euler DE, Mehra R, Seidl K, Slotwiner DJ, Mittal S et al. Do Atrial tachyarrhythmias beget ventricular tachyarrhythmias in defibrillator recipients? J Am Coll Cardiol 2002;40:335-40.
16. Bänsch D, Castrucci M, Böcker D, Breithardt G, Block M. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators. Incidence, prediction and significance. J Am Coll Cardiol 2000;36:557-65.
17. Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins; 2002.
18. Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol 2005;46:1712-20.
19. Raitt MH, Klein RC, Wyse DG, Wilkoff BL, Beckman K, Epstein AE et al. Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Am J Cardiol 2003;91:812-6.
20. Freedberg NA, Hill JN, Fogel RI, Prystowsky EN. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy. J Am Coll Cardiol 2001;37:1910-5.
21. Dorian P, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatia DS, Van Der Laan M et al. Analysis of all recurrent events is superior to the time-to-first event in assessment of drug therapy to prevent ICD therapies. Eur Heart J 2005;26:1737. P.
22. Otmani A, Trinquart L, Marijon E, Lavergne T, Waintraub X, Lepillier A et al. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study. Am Heart J 2009;158:230-7.
23. Vaughan Williams EM. Classification of anti-arrhythmic drugs. In: Sandoe E, Flensted-Jansen E, Olesen KH (eds). Symposium on Cardiac Arrhythmias. Sodertalje, Sweden: AB Astra; 1970. 449-72.
24. Harrison DA, Winkle RA, Sami M, Mason J. Encainide: a new and potent antiarrhythmic agent. In: Harrison DC (ed.). Cardiac Arrhythmias: A Decade of Progress. Boston, Mass: GK Hall; 1981. 315-30.
25. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
26. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle (the CASCADE study). Am J Cardiol 1993;72:280-7.
27. Mason JW, for the ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-8.
28. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
29. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 1999;353:9-13.
30. Woosley RL, Barbey JT, Wang T, Funck-Brentano C. Concentration/response relations for the multiple antiarrhythmic actions of sotalol. Am J Cardiol 1990;65:22A-27A.
31. Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. D, L-sotalol implantable cardioverter defibrillator study group. N Engl J Med 1999;340:1855-62.
32. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29.
33. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997;96:2823-9.
34. Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG et al. Amiodarone interaction with b-blockers analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. Circulation 1999;99:2268-75.
35. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES et al. Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. J Am Med Assoc 2006;295:165-71.
36. Carmeliet E. Voltage-and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992;262:809-17.
37. Boriani G, Lubinski A, Capucci A, Niederle P, Kornacewicz-Jack Z, Wnuk-Wojnar AM et al. A multicentre, double blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 2001;22:2180-91.
38. Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004;110:3646-54.
39. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
40. Kober L, Torp-Pedersen C, McMurray JJV, Gotzsche O, Levy S, Crijns H et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.
41. Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM et al. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol 2005;45:125-35.
42. Waleffe A, Mary-Rabine L, Legrand V, Demoulin JCI, Kulbertus HE. Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia. Am Heart J 1980;100:788-93.
43. Lee SD, Newman D, Ham M, Dorian P. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination:elimination of reverse use dependence. J Am Coll Cardiol 1997;29:100-5.
44. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357:2657-65.
45. Kuck K-H, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH) : a multicentre randomised controlled trial. Lancet 2010;375:31-40.
46. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter- defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol 1998;32:1909-15.
47. Exner DV, Pinski SL, Wyse DG, Renfroe EG, Follmann D, Gold M et al. Electrical storm presages nonsudden death: the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Circulation 2001;103:2066-71.
48. Greene M, Newman D, Geist M, Paquette M, Heng D, Dorian P. Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular tachyarrhythmias. Europace 2000;2:263-9.
49. Villacastín J, Almendral J, Arenal A, Albertos J, Ormaetxe J, Peinado R et al. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation 1996;93:753-62.
50. Hohnloser SH, Al-Khalidi HR, Pratt CM, Brum JM, Tatla DS, Tchou P et al. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. Eur Heart J 2006;27:3027-32.
51. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995;92:3255-63.
52. Kidwell GA, Greenspon AJ, Greenberg RM, Volosin KJ. Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans. Circulation 1993;87:118-25.
53. Josephson ME. Evaluation of antiarrhythmic agents. In: Josephson ME (ed.). Clinical Cardiac Electrophysiology: Techniques and Interpretations. Malvern, Pa: Lea and Febiger; 1993. 630-82.
54. Sweeney MO. Antitachycardia pacing for ventricular tachycardia using implantable cardioverter defibrillators: substrates, methods, and clinical experience. Pacing Clin Electrophysiol 2004;27:1292-305.
55. Goldschlager N, Epstein A, Friedman P, Gang E, Krol R, Olshansky B et al. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators. Arch Intern Med 2001;161:649-55.
56. Hook BG, Perlman RL, Callans DJ, Hanna MS, Kleiman RB, Flores BT et al. Acute and chronic cycle length dependent increase in ventricular pacing threshold. Pacing Clin Electrophysiol 1992;15:1437-44.
57. Rajawat YS, Patel VV, Gerstenfeld EP, Nayak H, Marchlinski FE. Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center. Pacing Clin Electrophysiol 2004;27:1670-81.
58. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997;80: 82G-89G.
59. Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold. the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006;114:104-9.
60. The DAVID Trial Investigators. Dual-Chamber Pacing or Ventricular Backup Pacing in Patients With an Implantable Defibrillator. J Am Med Assoc 2002;288:3115-23.
61. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sexbased differences and other issues. Am J Cardiol 2003;91:39D-44D.
62. Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM et al. A Randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 1995;6:687-99.